Abstract |
Clinical trials revealed that systemic administration of B-cell-depleting anti-CD20 antibodies can hold lesion formation in the early relapsing-remitting phase of multiple sclerosis (MS). Throughout the secondary-progressive (SP) course of MS, pathogenic B cells may, however, progressively replicate within the central nervous system (CNS) itself, which is largely inaccessible to systemic anti-CD20 treatment. Utilizing the murine MS model of experimental autoimmune encephalomyelitis, we show that intrathecal (i.t.) administration of anti-CD20 alone very efficiently depletes meningeal B cells from established CNS lesions. In SP-MS patients, adding i.t. administration of anti-CD20 to its systemic use may be a valuable strategy to target pathogenic B-cell function.
|
Authors | Klaus Lehmann-Horn, Silke Kinzel, Linda Feldmann, Florentine Radelfahr, Bernhard Hemmer, Sarah Traffehn, Claude C A Bernard, Christine Stadelmann, Wolfgang Brück, Martin S Weber |
Journal | Annals of clinical and translational neurology
(Ann Clin Transl Neurol)
Vol. 1
Issue 7
Pg. 490-6
(Jul 2014)
ISSN: 2328-9503 [Print] United States |
PMID | 25356419
(Publication Type: Journal Article)
|